eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) announced its participation in two upcoming investor conferences, emphasizing its focus on cancer treatment through selective translation regulator inhibitors (STRIs). The events include a Fireside Chat at Cantor's Future of Oncology Virtual Symposium on April 3, 2023, at 11 AM ET and another at Stifel's Targeted Oncology Days on April 25, 2023, at 2 PM ET. A live webcast of the Stifel event will be accessible on the company's Investors page, with replays available for 90 days. eFFECTOR is advancing innovative therapies targeting critical protein synthesis pathways to combat tumor growth, with lead candidate tomivosertib currently in Phase 2b trials.
- None.
- None.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences:
- Fireside Chat at Cantor’s the Future of Oncology Virtual Symposium on April 3, 2023 at 11am ET
- Fireside Chat at Stifel’s Targeted Oncology Days event on April 25, 2023 at 2pm ET
A live webcast of the Stifel event will be available on the "Events and Presentations" page of the Investors section of the Company’s website with a replay available for 90 days following the event. For more information, please visit investors.effector.com.
About eFFECTOR Therapeutics
eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.
Contacts:
| Investors: | Media: | |
| Christopher M. Calabrese Managing Director LifeSci Advisors 917-680-5608 ccalabrese@lifesciadvisors.com | Kevin Gardner Managing Director LifeSci Advisors 617-283-2856 kgardner@lifesciadvisors.com | Mike Tattory Account Supervisor LifeSci Communications 609-802-6265 mtattory@lifescicomms.com |
FAQ
What events is eFFECTOR Therapeutics participating in April 2023?
What is eFFECTOR Therapeutics' lead product candidate?
How can I access the webcast for eFFECTOR Therapeutics' investor events?
What are selective translation regulator inhibitors (STRIs) used for?
What partnerships does eFFECTOR Therapeutics have?
